


Company Registration No. 09364980 (England and Wales)

HEART BIOTECH LIPO LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
30 SEPTEMBER 2017
PAGES FOR FILING WITH REGISTRAR

SATURDAY



A22 *A788WSQ9* 16/06/2018 #143
COMPANIES HOUSE

HEART BIOTECH LIPO LIMITED**STATEMENT OF FINANCIAL POSITION****AS AT 30 SEPTEMBER 2017**

	Notes	2017 £	£	2016 £	£
Current assets					
Debtors	2	1		1	
		<u> </u>		<u> </u>	
Net current assets			<u> 1</u>		<u> 1</u>
Capital and reserves					
Called up share capital	3		<u> 1</u>		<u> 1</u>

The directors of the company have elected not to include a copy of the income statement within the financial statements.

For the financial year ended 30 September 2017 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved by the board of directors and authorised for issue on 12th June 2018 and are signed on its behalf by:



Professor M A Ishak-Hanna
Director

HEART BIOTECH LIPO LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 SEPTEMBER 2017

1 Accounting policies

Company information

Heart Biotech Lipo Limited is a private company limited by shares incorporated in England and Wales. The registered office is 17 North Drive, Littleton, Winchester, England, SO22 6QA.

Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

These financial statements are the first financial statements of Heart Biotech Lipo Limited prepared in accordance with FRS 102 as applied to smaller entities by the adoption of Section 1A of FRS 102. The financial statements of Heart Biotech Lipo Limited for the year ended 30 September 2016 were prepared in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

In accordance section 35 of FRS 102, Heart Biotech Lipo Limited has elected to retain its existing accounting policies for reported assets, liabilities and equity at the date of transition to FRS 102, until such time as it is not dormant.

Accordingly there are no transitional adjustments arising for the company on transition to FRS 102 that impact the company's previously reported financial performance or position.

Going concern

These financial statements have been prepared on a going concern basis, the validity of the assumption depends on the continued support of the Company's directors and support from other group companies. If the underlying support is withdrawn, it may be necessary to restate the accounts on a break-up basis.

Profit and loss account

The company has not traded during the year or the preceding financial period. During this time the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

HEART BIOTECH LIPO LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 SEPTEMBER 2017

1 Accounting policies (Continued)

Basic financial assets

Basic financial assets, which include amounts due from fellow group companies, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method.

Equity instruments

Equity instruments issued by the company are recorded at the fair value of proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2 Debtors

	2017 £	2016 £
Amounts falling due within one year:		
Amounts owed by group undertakings	1	1
	==	==

3 Called up share capital

	2017 £	2016 £
Ordinary share capital issued and fully paid:		
1 Ordinary of £1 each	1	1
	==	==